Clinical Trials Logo

Non-Melanoma Skin Cancers clinical trials

View clinical trials related to Non-Melanoma Skin Cancers.

Filter by:
  • None
  • Page 1

NCT ID: NCT05315128 Completed - Clinical trials for Non-melanoma Skin Cancers

Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers

Start date: July 6, 2020
Phase: Phase 2
Study type: Interventional

to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management

NCT ID: NCT04160065 Active, not recruiting - Clinical trials for Merkel Cell Carcinoma

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

Start date: March 3, 2020
Phase: Phase 1
Study type: Interventional

In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will be observed for any acute adverse events (AEs) post injection and for any delayed AEs at Day 28, 35 and/or 42 ± 7 days, depending on the cohort (exposure escalation and expansion design).

NCT ID: NCT02423863 Completed - Clinical trials for Head and Neck Cancer

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Poly-ICLC
Start date: March 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of sequential intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol®) for treatment of study subjects with accessible solid tumors, with or without checkpoint blockers. Enrolled study subjects will receive Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1 (Nivolumab, Pembrolizumab or Cemiplimab) or anti-PD-L1 (Atezolizumab or Durvalumab) over 6 months as defined in study treatment described below. MRI or CT imaging will be done per SOC at screening, 3 and 6-month time points.